Camber Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Camber Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$33M	Buy	600,000 +100,000	+20%	+$5.89M	3.1%	12
2025 Q1	$35.3M	Buy	500,000 +50,000	+11%	+$3.36M	1.26%	18
2024 Q4	$29.6M	Buy	+450,000	New	+$30.1M	0.68%	27
2024 Q3	–	Sell	-1,100,000	Closed	-$90.6M	–	36
2024 Q2	$90.6M	Buy	1,100,000 +850,000	+340%	+$70.8M	2.51%	14
2024 Q1	$21.8M	Buy	+250,000	New	+$22.4M	0.54%	28
2023 Q4	–	Sell	-300,000	Closed	-$26.5M	–	39
2023 Q3	$26.5M	Buy	+300,000	New	+$26.7M	0.87%	27
2022 Q4	–	Sell	-800,000	Closed	-$67.8M	–	41
2022 Q3	$67.8M	Sell	800,000 -700,000	-47%	-$62.3M	2.08%	19
2022 Q2	$124M	Buy	1,500,000 +200,000	+15%	+$15.9M	5.39%	5
2022 Q1	$100M	Buy	1,300,000 +285,000	+28%	+$23.8M	3.63%	13
2021 Q4	$89.7M	Sell	1,015,000 -135,000	-12%	-$11.1M	3.08%	12
2021 Q3	$88.9M	Buy	+1,150,000	New	+$90.7M	2.74%	16
2020 Q4	–	Sell	-400,000	Closed	-$30.4M	–	34
2020 Q3	$30.4M	Buy	+400,000	New	+$40.5M	1.61%	22

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Camber Capital Management's BMRN Position: Q2 2025 in Review

Camber Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q2 2025, buying an estimated $5.89M and bringing the position to 600,000 shares worth $33M. The position accounts for 3.1% of the portfolio, ranked #12.

Camber Capital Management first reported a position in BMRN in Q3 2020 and has held it in 12 quarters since. The position peaked at $124M in Q2 2022. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Camber Capital Management held 600,000 shares of BioMarin Pharmaceuticals worth $33M as of Q2 2025.
Camber Capital Management bought 100,000 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $5.89M.
BioMarin Pharmaceuticals made up 3.1% of Camber Capital Management's portfolio in Q2 2025, its #12 holding.
Camber Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 12 quarters since.
Camber Capital Management's BioMarin Pharmaceuticals position peaked at $124M in Q2 2022.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.